<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910114</url>
  </required_header>
  <id_info>
    <org_study_id>I002672</org_study_id>
    <nct_id>NCT03910114</nct_id>
  </id_info>
  <brief_title>Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography</brief_title>
  <official_title>Contrast Enhancement Characteristics of Gadolinium-Based-Contrast-Agents (GBCA) in Functional MR Urography (fMRU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Dotarem provides superior enhancement characteristics compared to other GBCA in
      fMRU

      Specific Aims: Compare enhancement characteristics of Dotarem to other GBCAs in the kidneys
      used in fMRU

      Primary Objectives: Review functional analysis curves and data of fMRU studies and determine
      enhancement characteristics in the kidneys of the three GBCAs (Dotarem, Gadovist, Magnevist)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective review will be performed of all functional MRI urography (fMRU) cases at two
      institutions (Children's Hospital of Philadelphia and Vanderbilt Children's Hospital). Over
      1000 studies have been performed between the institutions and the normal studies will be
      selected based on radiology reports and reviewed to confirm they are normal. The fMRU is
      performed with Gadolinium based contrast agents (GBCAs), initially was performed with
      Magnevist, then switched to Gadavist, and most recently converted to Dotarem. The fMRU
      software for analysis of the functional data provides enhancement curves of the aorta and
      kidneys. fMRU enhancement curves are generated by drawing regions of interest in the aorta
      and renal parenchyma and calculating the average signal intensity over time. A comparison of
      the enhancement curves will be performed of the three GBCAs in the normal pediatric
      population. The enhancement curves will provide peak enhancement values within the aorta and
      kidneys (Time to peak = TTP) and allow comparison between the GBCAs. The enhancement
      intensity versus time will be evaluated for each GBCAs, providing an evaluation of how long
      renal parenchymal enhancement is maintained. Additional functional data will be reviewed such
      as calyceal transit time (CTT) and renal transit time (RTT).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 1990</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dotarem TTP</measure>
    <time_frame>1 hour</time_frame>
    <description>The enhancement curves will provide peak enhancement values within the aorta and kidneys (Time to peak = TTP) and allow comparison between the GBCAs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gadovist TTP</measure>
    <time_frame>1 hour</time_frame>
    <description>The enhancement curves will provide peak enhancement values within the aorta and kidneys (Time to peak = TTP) and allow comparison between the GBCAs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnevist TTP</measure>
    <time_frame>1 hour</time_frame>
    <description>The enhancement curves will provide peak enhancement values within the aorta and kidneys (Time to peak = TTP) and allow comparison between the GBCAs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dotarem Time of Enhancement Intensity</measure>
    <time_frame>1 hour</time_frame>
    <description>The enhancement intensity versus time will be evaluated for each GBCAs, providing an evaluation of how long renal parenchymal enhancement is maintained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gadovist Time of Enhancement Intensity Time of Enhancement Intensity for Gadovist</measure>
    <time_frame>1 hour</time_frame>
    <description>The enhancement intensity versus time will be evaluated for each GBCAs, providing an evaluation of how long renal parenchymal enhancement is maintained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnevist Time of Enhancement Intensity Time of Enhancement Intensity for Gadovist</measure>
    <time_frame>1 hour</time_frame>
    <description>The enhancement intensity versus time will be evaluated for each GBCAs, providing an evaluation of how long renal parenchymal enhancement is maintained.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Magnetic Resonance Imaging Contrast Agents</condition>
  <arm_group>
    <arm_group_label>Dotarem Enhancement Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadovist Enhancement Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnevist Enhancement Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnevist</intervention_name>
    <description>GBCA enhancement</description>
    <arm_group_label>Magnevist Enhancement Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dotarem</intervention_name>
    <description>GBCA enhancement</description>
    <arm_group_label>Dotarem Enhancement Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadovist</intervention_name>
    <description>GBCA enhancement</description>
    <arm_group_label>Gadovist Enhancement Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric population which obtained MRI/fMRU study
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric population which obtained MRI/fMRU study

        Exclusion Criteria:

          -  Bilateral abnormal kidneys
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Childeen's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Aashim Bhatia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

